9 December 2014 A2M Pharma presents results of pilot proof of concept study for Quinpramine in alpha-synuclein model for Parkinson's Disease at the Michael J Fox Foundation. Quinpramine prevented mortality in a transgenic mouse model of Parkinson's Disease.
13 October 2014: A2M Pharma award winner at the Entente Life Science Investment Forum 2014; The Life Sciences Investment Forum united 28 European early stage innovative companies, selected from a pool of around 100 companies, active in the health sector and seeking investment opportunities and international exposure. The selected companies pitched their innovation, developments and needs in front of an international jury consisting of around 50 venture capitalists, corporate investors, business angels, and other industry experts.
23 September 2013: A2M Pharma receives a grant 'Quinpramine for Parkinson's Disease' as part of the 'Synuclein Therapeutic Acceleration Program'. more info
May 2012: A2M Pharma and LTS Lohmann start collaboration on a Isorotigotine transdermal delivery system
28 September 2009: A2M Pharma GmbH under TOP 10 during round 1 of business plan competition 'Medizinwirtschaft'. more info